UPCOMING EVENTS & PRESENTATIONS
3:00 PM IDT
Please see attached file for the agenda and Proxy Statement.
Contact Name: Kingsdale Advisors
Contact Email: email@example.com
Contact Phone USA: (888) 564-7333
Contact Phone Intl: +1-416-867-2272
8:30 AM EST
An abstract discussing the study’s top-line results, ‘A Phase III Randomized, Double Blind, Placebo-Controlled, Multicenter, Parallel Group Study To Assess The Efficacy And Safety Of Add-On Fixed-Dose Anti-Mycobacterial Therapy (RHB-104) In Moderately To Severely Active Crohn's Disease (MAP US)’ was presented as a late-breaking abstract today at the United European Gastroenterology Week (UEG Week 2018) by Dr. David Y. Graham, M.D., Professor of Medicine, Molecular Virology and Microbiology at Baylor College of Medicine, Houston and Lead Investigator of the MAP US study.